Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic surveillance of SARS-CoV-2 Omicron variants on a university campus.
Weil AA, Luiten KG, Casto AM, Bennett JC, O'Hanlon J, Han PD, Gamboa LS, McDermot E, Truong M, Gottlieb GS, Acker Z, Wolf CR, Magedson A, Chow EJ, Lo NK, Pothan LC, McDonald D, Wright TC, McCaffrey KM, Figgins MD, Englund JA, Boeckh M, Lockwood CM, Nickerson DA, Shendure J, Bedford T, Hughes JP, Starita LM, Chu HY. Weil AA, et al. Among authors: luiten kg. Nat Commun. 2022 Sep 6;13(1):5240. doi: 10.1038/s41467-022-32786-z. Nat Commun. 2022. PMID: 36068236 Free PMC article.
Evaluation of a novel university-based testing platform to increase access to SARS-CoV-2 testing during the COVID-19 pandemic in a cohort study.
Bennett JC, O'Hanlon J, Acker Z, Han PD, McDonald D, Wright T, Luiten KG, Regelbrugge L, McCaffrey KM, Pfau B, Wolf CR, Gottlieb GS, Hughes JP, Carone M, Starita LM, Chu HY, Weil AA. Bennett JC, et al. Among authors: luiten kg. BMJ Open. 2024 Jun 4;14(6):e081837. doi: 10.1136/bmjopen-2023-081837. BMJ Open. 2024. PMID: 38834321 Free PMC article.
Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
Bennett JC, Luiten KG, O'Hanlon J, Han PD, McDonald D, Wright T, Wolf CR, Lo NK, Acker Z, Regelbrugge L, McCaffrey KM, Pfau B, Stone J, Schwabe-Fry K, Lockwood CM, Guthrie BL, Gottlieb GS, Englund JA, Uyeki TM, Carone M, Starita LM, Weil AA, Chu HY. Bennett JC, et al. Among authors: luiten kg. Vaccine. 2024 Feb 27;42(6):1332-1341. doi: 10.1016/j.vaccine.2024.01.080. Epub 2024 Feb 1. Vaccine. 2024. PMID: 38307746